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Abstract. We examined whether baseline mortality risk, as a function of child age and site, modified the azithromycin
mortality-reduction effect in theMacrolideOraux pour Réduire lesDécès avec unOeil sur la Résistance (MORDOR) clinical
trial. We used the Cox proportional hazards model with an interaction term. Three models were examined representing
three sources for the baseline-risk covariate: two using sources external toMORDOR and the third leveraging data within
MORDOR. All three models provided moderate evidence for the effect becoming stronger with increasing baseline
mortality (P = 0.02, 0.02, and 0.07, respectively) at the rate of approximately 6–12% additional mortality reduction per
doubling of baseline mortality. Etiological and programmatic implications of these findings are discussed.
INTRODUCTION
The Macrolide Oraux pour Réduire les Décès avec un Oeil
sur la Résistance (MORDOR)† clinical trial conducted in
Malawi, Niger, and Tanzania provided significant evidence for
reduction in child mortality in sub-Saharan Africa, following
biannual mass administration of azithromycin.1 This evidence
has been further corroborated by a recent meta-analysis that
included data from two additional clinical trials, although
MORDORaccounted for the vastmajority of person-years (py)
and observed death events.2
Across these trials and inMORDOR in particular, there were
intriguing patterns that suggested mortality reduction might
be disproportionately concentrated in populations with higher
baseline mortality. MORDOR was powered for some sub-
group analyses: the Niger site had by far the highest mortality
rate, the strongest effect (18%mortality reduction, versus the
trial’s overall average estimate of 13.5%), and the only sig-
nificant single-site effect. Similarly, the youngest age group
(1–5 months old at treatment) suffered the highest baseline
mortality rate and also saw the strongest and most significant
mortality reduction (25%, averaged across all sites), followed
by the second youngest group (6–11 months at treatment,
14% reduction). However, the trial was not powered to detect
effect modification, and indeed the interactions between ef-
fect strength and either site or age were not significant.
The question whether effect magnitude is related to geo-
graphic and demographic factors, or to some other baseline
risk profile that incorporates such factors, has substantial
implications for planning future azithromycin interventions.
Therefore, we reanalyzed MORDOR data to examine whether
the baseline mortality rate, rather than age or site alone, is
associatedwith effectmagnitude.Whereas themainMORDOR
analysis was conducted at the randomization-cluster (“village”)
level, our analysis used individual survival histories. To test
sensitivity and robustness of potential effect modification, we
examined three different sources of data for baseline mortality.
Two of the sources were estimates external to MORDOR and
one was from within the study’s data.
METHODS
Data source. A redacted and de-identified version of
MORDOR data was prepared by T. C. P. MORDOR
study properties, and its main results were reported else-
where.1MORDORwasapprovedby theCommitteeonHuman
Research at the University of California, San Francisco; the
InstitutionalReviewBoardsat EmoryUniversity; theCollegeof
Medicine, the University of Malawi, Blantyre; the Niger Min-
istry of Health; the Tanzanian National Institute for Medical
Research; the London School of Hygiene and Tropical Medi-
cine; and the Johns Hopkins University School of Medicine.
Secondary analyses such as the present onewere covered by
these approvals. Jittered coordinates were provided for each
individual entry, but we used them only to calculate median
cluster coordinates, retaining individual de-identifiability
throughout the rest of the analysis.
Dataset preparation. The study consisted of four consec-
utive follow-up phases, each lasting approximately 6 months
on average. Individual child key, age at phase start, visit dates
(at which treatment or placebo was administered), and days in
follow-up for each phase were provided. Constructing self-
consistent individual histories was thus possible, but required
some straightforward data reconciliation, which affected ∼6%
of children. We provide further details in the Supplement.
Baselinemortality covariates.Thefirst source forbaseline-
mortality estimates was standard national cluster-sample sur-
veys: the Demographic and Health Survey (DHS) for Malawi
2015–2016 andTanzania 2015–2016, and theMultiple Indicator
Cluster Survey (MICS) for Niger, 2012.3–5 We used survey esti-
mates specific to the subnational regionswhereMORDOR took
place (Mangochi inMalawi, Dosso in Niger, and Eastern Region
inTanzania).Because theNigerMICSwas3yearsolder and that
survey showed a 5–6% per year mortality reduction during the
years leading up to 2012, we reduced Niger’s numbers by 15%
(a sensitivity analysis with no reduction showed similar overall
* Address correspondence to Assaf P. Oron, Institute for Disease
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results). Rates and standard errors were available for the 1- to
11-month-age and 12- to 59-month-age bins.
The second source provided by R. B. uses methods pub-
lished elsewhere: 1,000 posterior draws of child mortality
probability estimates from the Institute of Health Metrics and
Evaluation (IHME) Local Burden of Disease project on a 5 × 5-
km grid for a region covering each site.6 Mortality estimates
were available separately for 1- to 11-, 12- to 35-, and 36- to
59-month-age bins. For each study site and age bin, cluster-
median coordinateswerematched to the closest grid cell, and
averages (logit-transformed, which was the IHME model
scale) weighted by cluster population were calculated for
each posterior draw.
With both sets of external estimates, a gradual transition
between discrete age bins is warranted, for several reasons.
Because the average phase duration was 6 months, most
children treatedat 6–11monthsof age (andalso, 30–35months
in the IHME case) matured into the next age bin during the
phase. In addition, a dramatic, instantaneous drop in mortality
risk at exactly 12 months is unrealistic. Last, there was strong
“heaping”of reported agesevery 6months, inparticular around
12 months of age. Therefore, rather than using two to three
constant mortality rates per site, we linearly interpolated mor-
tality rates within 6 months of age bin boundaries (between 6
and 18months of age, and also between 30 and 42months for
the IHME estimates; see Figure 1).
The third set of baseline mortality estimates was derived
from MORDOR data, by estimating survival as a smooth
function of treatment age separately for each site and phase,
averaged across both arms, via generalized additive models
with a Cox survival link (R package mgcv).
Uncertainty of baseline-mortality estimates in the models,
regardless of source, was accounted for by assuming they
were missing and using standard imputation techniques
guided by each source’s standard errors.7 We used B = 400
imputations for all models.
Statisticalmodel. For each baseline-mortality data source,
we fitted a separate Cox proportional hazards regression
model with a time-varying baseline-mortality covariate (i.e., a
different covariate value for each child–phase combination).
The effect of interest was interaction between treatment arm







where i, s, a, and p are the individual, site, arm, and phase
indicators, respectively; λ0 and λip are the baseline mortality
hazard (stratified by site and phase) and individual i’s specific
hazard curve during phase p, respectively; logR is the loga-
rithm of the baseline-mortality covariate described previously
(transformed tomatch theCoxmodel’s log-hazard scale); and
age and Tage are continuous age (used as the model’s uni-
versal “time counter”) and age at treatment, which remains
fixedover time for each individual–phase combination. Finally,
βa, βR, and βmod are the effect sizes of the azithromycin (AZM)
arm, baseline mortality, and their interaction, respectively.
FIGURE 1. Externally derived baseline mortality curves used as risk covariates in the model. Left: Demographic and Health Survey (DHS) and
Multiple Indicator Cluster Survey (MICS) estimates. Right: Institute of Health Metrics and Evaluation (IHME) local burden estimates. The bands
indicate 95% CIs. The dots in both panes indicate crude observed mortality rates in Macrolide Oraux pour Réduire les Décès avec un Oeil sur la
Résistance (MORDOR) placebo arm, calculated by site and 3-month-age bins. This figure appears in color at www.ajtmh.org.
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Robust standard errors were calculated, to account for ob-
servation clustering by randomization unit.
The baseline mortality predictor was centered around 15
deaths per 1,000 py, roughly equivalent to under-5 mortality
probability of 100 per 1,000 live births, assuming neonatal
mortality probability of 25–30 per 1,000 live births, typical to
most of sub-Saharan Africa. This rate is also close to the
overall mean mortality rate observed during MORDOR. For
inference, we used the classical asymptotic test on the in-
teraction term’s imputation t-statistic. Given the post hoc
nature of our analysis, we considered P < 0.01 as significant,
whereas 0.01 £ P < 0.1 was accorded the intermediate status
of indicative evidence. All analyseswere performed byA. P. O.
using R (The R Foundation for Statistical Computing, Vienna,
Austria). Additional model details appear in the Supplement.
RESULTS
The individually reconciled dataset follows 270,229 child
histories over 337,966 py, with 4,990 mortality events across
the three sites: 72% of them in Niger, 21% in Malawi, and 7%
in Tanzania. Figure 1 shows mortality rates observed on the
placebo arm in each site separately, binned by 3-month age
intervals (dots). In Niger and Tanzania, mortality rates peaked
among infants treated during the second quarter of life, and in
Malawi, they were worst among the youngest infants. Rates
decreased dramatically after the first birthday, but less so in
Niger, which had the highestmortality rates at all age bins. The
IHME-derived baseline mortality estimates (right, solid lines
with uncertainty bands) showmarkedly better agreement with
observed MORDOR patterns than the DHS/MICS-derived
lines (left).
Toprovide aperspective oneffectmodificationdirectly from
the raw data, Figure 2 shows the placebo rates from Figure 1
versus the rate differences between the arms. A perfectly
proportional azithromycin effect (i.e., no effect modification)
would trace a diagonal linear pattern from the origin. By con-
trast, the observed pattern does not substantially depart from
zero effect until a mortality rate of∼10 deaths/1,000 py. At the
high-mortality end, the effect increases nonlinearly. The latter
pattern is driven by Niger data only, as this was the only site
with observed age-bin placebomortality rates greater than 25
deaths/1,000 py. However, observations from all three sites
overlap in the range of 10–25 deaths/1,000 py, where they all
seem to follow a similar trend.
Figure 3 shows the estimates and 99% CIs for effect
modification in the full models, using the three sources of
baseline-mortality rates (right), as well as the estimated effect
at the referencebaseline risk of 15deathsper 1,000py (left). All
models indicate someenhancement of the azithromycin effect
with increasing baseline risk; an enhancement that is in-
dicative, yet not significant at α = 0.01. Specifically, the DHS/
MICS-informed model suggests 11.7% additional mortality
reduction asbaseline risk is doubled (99%CI:−22.9%,+1.1%;
P= 0.02), the IHME-informedmodel indicates 8.9%additional
reduction (99% CI: −17.6%,+0.6%; P = 0.02), and the model
using estimates derived from MORDOR data indicated 5.6%
additional reduction per doubling (99% CI: −12.9%,+2.3%;
P = 0.07).
Azithromycin effect estimates at the reference rate of 15/
1,000 py (Figure 3, left) show the reverse order, with the DHS/
MICS model indiating a relatively weak effect at this baseline
rate (8.7% reduction, 99% CI: −3.2%,19.2%; P = 0.06), the
IHME model significant and close to the mean MORDOR
FIGURE 2. Observed mortality rates calculated by site and 3-month-age bins: placebo rates (x axis) vs. the difference between the arms (y axis).
Negative difference indicates net mortality reduction on the azithromycin arm. Site is indicated by circle color and age group by the circle outlines’
shadeofgray. Thesolidblackcurve is anempirical locally estimatedscatterplot smoothing (LOESS)fit using spanparameter 0.75.Comparewith ref.
2, Fig. 2. This figure appears in color at www.ajtmh.org.
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effect (12.0% reduction, 99%CI: 2.2%,20.7%;P=0.002), and
the MORDOR-derived model strongest (17.3% reduction,
99% CI: 7.1%,26.3%; P < 0.001).
Figure 4 illustrates the three estimated model curves as a
function of baseline mortality. The externally informedmodels
trace similar trajectories, slightly detrimental (but certainly not
significant) at very low mortality rates, remaining weaker than
the average MORDOR estimate of 13.5% mortality reduction
(diagonal blue line) until ∼20 deaths/1,000 py, and becoming
stronger after that. The MORDOR-derived curve is closer to
linear and shows a stronger effect almost throughout.
DISCUSSION
A concurrent article examines the baseline-mortality effect
modification question using a complementary approach,
FIGURE 3. Estimates from the effect-modificationmodelswith 99%CIs. Left: themain effect at a baseline risk of 15 deaths per 1,000 py. The blue
line marks the overall Macrolide Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) estimate of 13.5% mortality reduction.
Right: effect modification by baseline risk, represented as additional mortality reduction per doubling of baseline risk. This figure appears in color at
www.ajtmh.org.
FIGURE 4. Fitted effect-size curves from the three interactionmodels. The diagonal blue line indicates the averageMacrolideOraux pour Réduire
lesDécès avec unOeil sur la Résistance (MORDOR) effect with no interaction. The age-bin observations fromFigure 2 are added in the background
as visual reference. This figure appears in color at www.ajtmh.org.
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namely, splitting each MORDOR study region into rectan-
gles.8 That article’s regression model is fitted at the
subregional-summary level rather than using individual his-
tories, and also incorporates all studies used in Oldenburg
et al.’s2 meta-analysis. Its baseline-mortality variable is most
closely related to our model that uses within-MORDOR mor-
tality estimates. It implicitly assumes that the effect is age-
agnostic (except, to a limitedextent, in their sensitivity analysis
adjusting for median age), whereas our article implicitly as-
sumes that baseline mortality is identical for same-age chil-
dren within each site. Despite these differences, when
restricted to MORDOR data only, the other article finds evi-
dence at a significance level similar to ours (P = 0.04), but on
addition of data from two much smaller studies, the evidence
becomes substantially weaker (P = 0.12), mostly because of
one of those studies9 showing a very strong effect at relatively
low baseline mortality (ref. 8, Fig. 1).
Our modeling approach assumes that mortality-risk varia-
tions due to location or age are interchangeable with respect
to the azithromycin effect. If the assumption does not hold,
then the similar effect magnitudes observed in MORDOR
among 3 to 4-year-olds in Niger and infants in the other two
sites are due to chance variations, or to other factors unrelated
to baseline mortality.
Although using data from within MORDOR for baseline-risk
estimationmayseemattractiveat facevalue, suchestimatesare
almost inevitably subject to endogeneity bias. Our approach
made sure this bias is conservative, which may explain the at-
tenuated interaction estimate compared with the models using
external data.Wedeem theDHSandMICSestimates at least as
reliable for addressing the question of interest. These estimates
were derived completely independently of MORDOR, via an
established survey approach widely considered a gold stan-
dard. The IHMEmortality estimates use the very sameDHSand
MICS surveys as their main mortality data source. Institute of
Health Metrics and Evaluation 5 × 5 km grid estimates are also
informed by survey household locations, cross-validated re-
gression models using additional geographical variables, and
spatial smoothing (ref. 6, Supplemental Material). Individual
grid-cell estimates may be less precise in some locations, but
our approach population-averages them over hundreds of grid
points in each site, and is therefore considerably more robust.
MORDOR’s endpoint is all-causemortality, but azithromycin
should not have a substantial effect on noninfectious or viral
infectious deaths. Therefore, the statistical tool of an in-
teraction model is only a blunt proxy to any possible effect
modification etiology. This alsomeans that interactionmodels
are an inherently conservative approach to detecting effect
modification in this context. As to the etiology itself, the most
direct explanation for a baseline-mortality effect modification
is that higher childmortality rates are usually driven by a higher
proportion of infectious deaths, especially after the firstmonth
of life.10 In the absence of evidence for association of the
azithromycin effect with specific diseases, this is probably
also our best explanation.
From a programmatic perspective, even with no effect
modification, more lives per dose would be saved in higher
mortality populations. Therefore, the moderate evidence for a
disproportionately stronger effect in those populations may
provide further justification for prioritizing them. In this con-
text, our analysis views “populations” as defined by both lo-
cation and age: children of different ages in the same location
face very different baseline risks. Therefore, the plans already
underway tocorroborate the effect among infants via additional
clinical trials that leverage existing delivery schemes, for ex-
ample, routine immunization systems, should be accelerated.
Such trials should be implemented also in some regions re-
sembling the Malawi and Tanzania sites rather than only in the
highest mortality regions. It should be noted that postneonatal
infants experience a mortality risk of > 15/1,000 py across a far
greater part of sub-Saharan Africa than older children.
With these suggestions in mind, the overarching goal must
be for all children to enjoy a sufficiently healthy childhood in
good living conditions, so that they will not need antibiotic
prophylaxis to help themsurvive. Azithromycin can savemany
lives in the short andmedium term, and should be viewed as a
bridge for safer and faster transition to better conditions.
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